Ligand News and Research

RSS

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer.

21 Feb 2020

Novel melatonin receptor molecules potentially address circadian rhythm disturbances

Like breathing or blinking, behaviors regulated by our circadian rhythms, such as digestion and sleep-wake cycles, go unnoticed by most people.

10 Feb 2020

Researchers reveal new activity above the surface in brain-cell receptors

Like buoys bobbing on the ocean, many receptors float on the surface of a cell's membrane with a part sticking above the water and another underwater, inside the cell's cytoplasm.

7 Feb 2020

Purdue-developed 'fluorescent markers' begin Phase 3 clinical trials

On Target Laboratories Inc., a privately held biotechnology company developing the use of Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26% of patients undergoing pulmonary resection for non-small-cell lung cancer.

6 Feb 2020

Biophysicists shed light on the structure, functioning mechanism of CysLT receptors

Biophysicists from the MIPT Center for Molecular Mechanisms of Aging and Age-Related Diseases have teamed up with colleagues from Canada, the U.S., Japan, France, and Germany to shed light on the structure and functioning mechanism of the CysLT receptors, which regulate inflammatory responses associated with allergic disorders.

21 Jan 2020

Smoking dormant HIV virus out into the open to develop a cure

Ever since antiretroviral treatments against HIV infection were introduced in 1996, scientists have eagerly been hunting for a cure for the disease.

9 Jan 2020

Discovery could pave way for new breast cancer drugs

Eric Prossnitz, PhD, hopes to help many of the 12% of American women who are projected to be diagnosed with breast cancer in their lifetimes.

7 Jan 2020

Study finds new drivers of destructive inflammation

Scientists describe in Nature Immunology an entirely new molecular process in mice that triggers T cell-driven inflammation and causes different auto-immune diseases.

17 Dec 2019

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.

16 Dec 2019

Researchers investigate NOTCH1 mutations in keratinocyte lines derived from OSCC biopsies

The cover for issue 63 of Oncotarget features Figure 6, "Inverse relationship between ETV7 and SERPINE1 in OSCC," by Salameti, et al.

4 Dec 2019

Streamlining Immuno-Oncological Therapeutic Antibody Discovery

The growing trend of implementing immunotherapy into oncology has resulted in various new therapeutic cancer treatments utilizing antibodies.

From Sartorius 3 Dec 2019

New computational method can help predict and design allosteric functions in proteins

Called the "second secret of life", allostery is one of the most fundamental processes of biology and has been a central focus among scientists across the life sciences spectrum, from fundamental biology to drug development.

3 Dec 2019

Attacking HIV at the source

A new study published on November 26, 2019, in the journal Cell Reports, details a new discovery that may help avert HIV infection right at the start. The virus is known to take a long time to infect a person, and the scientists say they have found a period during which it can be weakened or killed, in the very first hours after it has entered a host. They call this the window of vulnerability.

26 Nov 2019

New way to thwart HIV infection at early stages

1.7 million. That's how many people are infected with the human immunodeficiency virus (HIV) each year worldwide. 1.7 million people who are condemned to lifelong antiretroviral therapy (ART) or risk developing fatal AIDS . Out of the 37.9 million people living with HIV (PLWH), 22.3 million have access to ART, allowing them to have an almost normal lifespan.

26 Nov 2019

Cell factors decide if a cancer grows or dies, says new study

A new study published today in the journal Cell Reports by scientists at the German Cancer Research Center (DKFZ) shows that the direction taken by a cancer cell depends on the configuration of the cell itself as well as the activation of a universal cancer cell receptor called CD95.

19 Nov 2019

Researchers discover new pathway to 'reprogram' killer cells

Killer cells of the immune system detect and kill infected cells or cancer cells. Researchers at the Institute of Pathology at the University of Bern have now discovered that the mechanism by which certain immune cells kill their target cells can also be used to control the killer cells themselves.

19 Nov 2019

Dopamine D2 receptor modulates Wnt expression, controls cell proliferation

The dopamine D2 receptor has a previously unobserved role in modulating Wnt expression and control of cell proliferation, according to a new study from the George Washington University and the University of Pittsburgh.

14 Nov 2019

Fresh light on why aggressive breast tumors form and how they can be treated

New research presented at the Society for Endocrinology annual conference in Brighton appears to identify novel methods of therapy for an aggressive type of breast cancer as well as uncovering potential causative factors. The focus of the study is to show how common chemicals present in our surroundings are possibly putting women at risk of a type of breast cancer called triple negative breast cancer (TNBC).

12 Nov 2019

Investigators use the power of computation to build better targeted drug therapy

Antibody drug conjugates (ADCs) -- cancer drugs that are designed to target and destroy cancerous tissue while leaving healthy cells intact -- represent a long sought-after advancement in cancer therapy.

8 Nov 2019

Experimental drug targets currently untreatable type of lung cancer

Scientists at Stanford and UC-San Francisco have developed an experimental drug that targets a currently untreatable type of lung cancer responsible for generating roughly 500,000 newly diagnosed cases worldwide each year.

7 Nov 2019